Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Up 198.4% in May

Traws Pharma, Inc. (NASDAQ:TRAW) saw a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,671,345 shares, an increase of 198.4% from the April 30th total of 560,036 shares. Based on an average trading volume of 10,790,912 shares, the short-interest ratio is currently 0.2 days. Currently, 19.1% of the shares of the stock are short sold.

Traws Pharma Price Performance

NASDAQ TRAW traded down $0.06 during trading hours on Friday, reaching $1.46. The company’s stock had a trading volume of 376,268 shares, compared to its average volume of 6,455,541. The firm has a fifty day simple moving average of $1.61 and a 200-day simple moving average of $1.80. The stock has a market cap of $14.83 million, a P/E ratio of -0.86 and a beta of 1.47. Traws Pharma has a 52 week low of $1.00 and a 52 week high of $3.27.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.39. On average, research analysts expect that Traws Pharma will post -2.23 earnings per share for the current year.

Wall Street Analyst Weigh In

TRAW has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Traws Pharma to a “strong sell” rating in a research note on Saturday. LADENBURG THALM/SH SH upgraded shares of Traws Pharma to a “strong-buy” rating in a research note on Friday, January 30th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Traws Pharma in a research note on Wednesday, May 20th. Finally, Weiss Ratings downgraded shares of Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Traws Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Insider Buying and Selling at Traws Pharma

In related news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of Traws Pharma stock in a transaction dated Thursday, April 16th. The shares were bought at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the purchase, the insider owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TRAW. State Street Corp bought a new position in Traws Pharma in the 4th quarter valued at approximately $29,000. Two Sigma Investments LP raised its holdings in Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares during the last quarter. XTX Topco Ltd raised its holdings in Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after purchasing an additional 31,502 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in Traws Pharma during the 4th quarter worth approximately $56,000. Finally, Geode Capital Management LLC raised its holdings in Traws Pharma by 41.9% during the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares during the last quarter. Institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.